Regulatory Approvals and Recognitions - In 2023, the company received approval from the National Medical Products Administration for the quality standard improvement and specification change of its seabuckthorn syrup product[6]. - The company was recognized as an "A-level taxpayer" for the 8th consecutive year by the Hohhot Taxation Bureau, reflecting its commitment to integrity and legal tax payment[6]. - The company was awarded the "Top 100 Tax Contributors" in Hohhot for the year 2022 by the Hohhot Municipal Government[6]. - The company has been recognized as an "Innovative Small and Medium-sized Enterprise" by the Inner Mongolia Ministry of Industry and Information Technology[6]. - The company is recognized as a "high-tech enterprise," indicating its commitment to innovation and technological advancement[46]. Financial Performance - The company's operating revenue for 2023 reached ¥188,252,662.38, representing a 19.39% increase compared to ¥157,678,436.36 in 2022[29]. - The net profit attributable to shareholders decreased by 46.71% to ¥7,927,636.45 from ¥14,876,821.45 in the previous year[29]. - The gross profit margin for 2023 was 71.42%, down from 72.46% in 2022[29]. - Total assets increased by 14.55% to ¥740,257,570.88 from ¥646,206,052.72 at the end of 2022[31]. - Total liabilities rose by 54.02% to ¥251,918,583.61 compared to ¥163,557,601.90 in 2022[31]. - The company's basic earnings per share decreased by 40.00% to ¥0.03 from ¥0.05 in 2022[29]. - The cash flow from operating activities showed a negative net amount of ¥21,125,533.75, a significant decline from ¥101,836,479.47 in 2022[31]. - Non-recurring gains and losses totaled ¥8,184,642.38 in 2023, down from ¥15,268,132.10 in 2022[37]. - The weighted average return on net assets (excluding non-recurring gains) was 0.19% in 2023, compared to 0.37% in 2022[29]. Research and Development - The company is developing a new technology for the inspection of seabuckthorn products, which has been approved by the Inner Mongolia Science and Technology Department[6]. - The company has submitted a key project application for the modernization of traditional Chinese medicine, collaborating with several prestigious institutions[6]. - The company is engaged in multiple R&D projects, including the development of new extraction methods for Mongolian medicinal materials, which are expected to enhance product quality and market competitiveness[90]. - The company completed a sub-project on the effective components extraction and preparation process of seabuckthorn juice in collaboration with Shenyang Pharmaceutical University[91]. - The company is involved in a project with Tianjin University of Traditional Chinese Medicine focusing on the scientific research of traditional Chinese medicine for aging control, including the extraction and formulation processes of various products[91]. - The company has been awarded the title of "Innovative Small and Medium-sized Enterprises," indicating its commitment to innovation and development[200]. Market and Sales Strategy - The company plans to increase investment in marketing system construction and brand promotion to expand market coverage and enhance brand recognition[48]. - The company aims to enhance its market share in the hospital system and OTC sectors for Mongolian medicine, leveraging its resources and R&D capabilities[105]. - The company plans to deepen its distribution channels for specialty OTC products and strengthen partnerships with top 100 retail chains[106]. - The company is actively pursuing market expansion and product innovation to strengthen its position in the pharmaceutical industry[90]. - The company has established stable supplier relationships to manage raw material price fluctuations[111]. Production and Quality Control - The construction of the Datang Health Technology Industrial Park is set to include 13 production lines, enhancing equipment technology and product quality to meet future business growth demands[47]. - The company has obtained the necessary drug production licenses and established a comprehensive quality management system[111]. - The company has developed a new production process for Wu Zhu Yu medicinal materials, enhancing the effective component content and ensuring product consistency and stability[198]. - The honey pill production process has been improved, increasing product quality and stability through advanced honey refining technology[198]. - The company has optimized the production process for liver and kidney granules, enhancing internal quality control standards[198]. Employee and Management Information - The company reported a total of 259 employees at the end of the period, an increase of 15.11% from 225 employees at the beginning of the period[177]. - The company established a comprehensive salary system and performance evaluation system to enhance employee retention and development[179]. - The total number of shares held by the board members and supervisors at the end of the reporting period was 14,339,877, accounting for 5.5413% of total shares[169]. - The company has set performance evaluation indicators for senior management based on the 2023 operational goals, linking their compensation directly to performance outcomes[173]. Shareholder and Stock Information - The company’s total share capital is 258,777,181 shares, with no preferred shares issued[23]. - The company’s total share capital decreased from 261,017,281 shares to 258,790,681 shares after the completion of the stock repurchase[130]. - The company’s management confirmed that the stock repurchase will not adversely affect the company's performance or financial status[131]. - The company has not proposed any cash dividend distribution plan despite having positive undistributed profits[162]. - The company’s stock price at the end of the reporting period was 6.00 yuan per share[176]. Risks and Challenges - The company faces challenges in attracting talent due to its remote location, which may impact its operational goals[109]. - The company acknowledges potential delays in R&D progress due to various uncertainties and plans to collaborate with external experts to ensure timely execution[109]. - The company is subject to strict regulatory oversight, and failure to comply with national drug regulations could significantly impact its operations[110]. - The trend of drug price reduction in China is expected to continue, impacting overall market prices[111]. Related Party Transactions and Legal Matters - The company has engaged in significant related party transactions amounting to CNY 55 million[119]. - The company has not experienced any major litigation or arbitration matters during the reporting period[116]. - The company provided a mortgage guarantee of CNY 55 million for a loan from Everbright Bank to its controlling shareholder, which has been canceled[120].

证券代码：836433 证券简称：大唐药业 公告编号：2024-008 内蒙古大唐药业股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 项目签字注册会计师张洁：于2019年12月成为注册会计师、2018年12月开 始从事上市公司和挂牌公司审计、2020年09月开始在本所执业；近三年签署上 市公司和挂牌公司审计报告数量超过2家次。 （二）独立性和诚信情况 新任项目签字注册会计师张洁不存在违反《中国注册会计师职业道德守则》 对独立性要求的情形，最近三年未受到过刑事处罚、行政处罚、行政监管措施 和自律处分。符合定期轮换的规定，无不良诚信记录。 三、对公司的影响 本次变更过程中相关工作安排有序交接，变更事项不会对公司2023年度财 务报表及内部控制审计及项目质量复核工作产生影响。 内蒙古大唐药业股份有限公司（以下简称"公司"）于2023年4月24日召开 第三届董事会第十一次会议，审议通过了《关于续聘公司2023年度审计机构的 议案》，同意续聘大华会计师事务所（特殊普通合 ...

Financial Performance - The net profit attributable to shareholders for 2023 is expected to be 7.644 million yuan, a decrease of 48.61% compared to 14.8731 million yuan in the same period last year[3]. - The decline in net profit is primarily due to a reduction in government subsidies received, increased marketing expenses, and a decrease in investment income from bank financial products[4][5]. Expenses and Investments - The company has increased its market investment efforts to further expand sales channels, leading to higher sales expenses compared to the previous year[4]. - The company has also seen an increase in inventory impairment provisions and depreciation expenses due to the ongoing construction of the health technology industrial park project[5]. Financial Reporting - The financial data presented is preliminary and has not been audited by an accounting firm, urging investors to be cautious about investment risks[6].

Financial Performance - The company's operating revenue for 2023 reached ¥188,252,662.38, representing a year-on-year increase of 19.39%[4] - Net profit attributable to shareholders decreased by 48.61% to ¥7,644,018.38, while the net profit after deducting non-recurring gains and losses fell by 56.46% to ¥815,857.82[4] - Basic earnings per share dropped by 40% to ¥0.03, reflecting the decline in net profit[5] Assets and Equity - Total assets at the end of the reporting period amounted to ¥739,931,642.46, an increase of 14.51% compared to the beginning of the period[5] - Shareholders' equity attributable to the company increased by 1.12% to ¥488,047,942.98, with net assets per share rising by 2.16% to ¥1.89[5] Factors Affecting Profit - The decline in net profit was primarily due to reduced government subsidies, increased marketing expenses, and lower investment income from bank financial products[6] Market Expansion - The company expanded its market presence by enhancing sales channels, particularly in third-party and grassroots medical sales, contributing to revenue growth[6] Project Transition and Expenses - The company is currently transitioning its health technology industrial park project, leading to increased depreciation expenses[6] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[7] - The company emphasizes the importance of monitoring investment risks associated with the preliminary financial data[7]

| | 公告日期 2024-02-07 | 异常期间 | 无 | | | | --- | --- | --- | --- | --- | --- | | | 大唐药业(836433) 连续竞价 | 成交数量 | 26283202.0 | 成交金额（万 | 14493.4 | | | | （股） | | 元） | | | | 涉及事项 当日收盘价涨幅达到20%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 东亚前海证券有限责任公司上海分公司 | | | 6398066.3 | 744789.22 | | 买2 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | | | 2859959.76 | 1742888.35 | | 买3 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | | 2771865.74 | 1562891.02 | | 买4 | 广发证券股份有限公司广州天河路营业部 | | | 2402828 | 3439729.79 | | 买5 | 东方财富证券股份有限公司拉萨东环路第一证券营业部 ...

| | 公告日期 2024-02-07 | | 异常期间 | 2024-02-07 | | | | --- | --- | --- | --- | --- | --- | --- | | | 大唐药业(836433) | 连续竞价 | 成交数量 （股） | 41763051.0 | 成交金额（万 元） | 21355.57 | | | 北交所股票最近3个有成交的交易日以内收盘价涨跌幅偏离值累计达到+40% 涉及事项 | | | | | | | | (-40%) | | | | | | | 买/卖 | 营业部或交易单元名称 | | | | 买入金额（元） | 卖出金额（元） | | 买1 | 东亚前海证券有限责任公司上海分公司 | | | | 7016700.64 | 744789.22 | | 买2 | 广发证券股份有限公司广州天河路营业部 | | | | 5316987.38 | 3440190.79 | | 买3 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | | | | 3645639.98 | 2670020.78 | | 买4 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-02- | | | | | 异常期间涨跌幅偏离值累计 | | 07 | 873305 | 九菱科技 | 10215627.0 | 20132.05 | 达到60.05% | | 2024-02- | 836433 | 大唐药业 | 41763051.0 | 21355.57 | 异常期间涨跌幅偏离值累计 | | 07 | | | | | 达到49.44% | | 2024-02- | | 西磁科技 | | | 当日收盘价涨幅达到29.96% | | 07 | 836961 | | 6527182 | 12978.7 | | | 2024-02- | 873305 | 九菱科技 | 6826504 | 14538.51 | 当日收盘价涨幅达到29.95% | | 07 | | | | | | | 2024-02- | 833580 | 科创新材 | 8485963 | 6058.45 | 当日收盘价涨幅达到29.86% | | 07 ...

证券代码：836433 证券简称:大唐药业 公告编号：2024-005 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、股票交易异常波动的具体情况 公司股票最近 2 个有成交的交易日（2024 年 2 月 6 日、2024 年 2 月 7 日）以内收盘价 涨幅偏离值累计达到 49.44%，根据《北京证券交易所交易规则（试行）》的有关规定，属于 股票异常交易波动情形。 二、公司关注并核实的相关情况 1、 关注问题： (1)前期公告的事项是否取得重大进展或变化，前期披露的公告是否需要更正、补充； (2)是否存在可能或已经对本公司股票交易价格产生较大影响的媒体报道或市场传闻， 是否涉及热点概念事项； (3)近期公司经营情况及内外部经营环境是否或预计将要发生重大变化； (4)公司、控股股东和实际控制人是否存在关于本公司的应披露而未披露的重大事项， 或处于筹划阶段的重大事项； 内蒙古大唐药业股份有限公司股票交易异常波动公告 电话询问、口头询问等方式。 4、 核实结论： 前期公告的事项不存在需要更正、补充之处，或 ...

三、备查文件 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、生产药品备案情况 近日，内蒙古大唐药业股份有限公司（以下简称"公司"）已完成公司产品 安宫牛黄丸在内蒙古自治区药品监督管理局备案手续，主要备案内容：申请安 宫牛黄丸处方中以"牛黄"等量替代"体外培育牛黄"投料使用，以"麝香" 等量替代"人工麝香"投料使用。 二、对公司的影响 本次公司申请安宫牛黄丸处方中以"牛黄"等量替代"体外培育牛黄"投 料使用，以"麝香"等量替代"人工麝香"投料使用，对公司未来的经营将产 生积极影响。短期内，对公司财务状况和经营成果不会产生较大影响。对于收 入贡献具有一定不确定性，敬请广大投资者理性投资，注意投资风险。 证券代码：836433 证券简称：大唐药业 公告编号：2024-004 内蒙古大唐药业股份有限公司 关于药品安宫牛黄丸完成备案的公告 《国家药品监督管理局网站境内生产药品备案信息公示》 内蒙古大唐药业股份有限公司 董事会 2024 年 2 月 7 日 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 证券代码：836433 证券简称：大唐药业 公告编号：2024-003 内蒙古大唐药业股份有限公司 关于"同泰永"品牌被认定为中华老字号的公告 特此公告。 内蒙古大唐药业股份有限公司 董事会 2024 年 2 月 2 日 近日，内蒙古大唐药业股份有限公司（以下简称"公司"）从国家商务部 网站获悉，根据《商务部等 5 部门关于公布第三批中华老字号名单的通知》， 公司"同泰永"品牌成功被商务部、文化和旅游部、市场监管总局、国家知识 产权局、国家文物局等五部门认定为第三批中华老字号。 本次中华老字号认定，是根据《中华老字号示范创建管理办法》，经企业 申报、地方推荐、社会公示，商务部、文化和旅游部、市场监管总局、国家知 识产权局、国家文物局以"优中选优"的原则决定，旨在推动老字号守正创新 发展。 下一步，公司将积极做好引领示范作用，充分发挥老字号在质量管理、品 牌建设、文化传承等方面的优势，实现公司高质量发展。 ...